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Abstract: Adolescents are a critical population that is disproportionately impacted by the HIV 
epidemic. More than 2 million adolescents between the age group of 10 and 19 years are living 
with HIV, and millions are at risk of infection. HIV risks are considerably higher among girls, 
especially in high-prevalence settings such as eastern and southern Africa. In addition to girls, 
there are other vulnerable adolescent subgroups, such as teenagers, who use intravenous (IV) 
drugs, gay and bisexual boys, transgender youth, male sex workers, and people who fall into 
more than one of these categories. Pre-exposure prophylaxis (PrEP) is a new intervention for 
people at high risk for acquiring HIV, with an estimated HIV incidence of >3%. Recent data 
from trials show evidence of the efficacy of PrEP as a powerful HIV prevention tool in high-risk 
populations, including men who have sex with men, HIV-1-serodiscordant heterosexual couples, 
and IV drug users. The reported efficacy in those trials of the daily use of oral tenofovir, alone or 
in combination with emtricitabine, to prevent HIV infection ranged from 44% to 75% and was 
heavily dependent on adherence. Despite the proven efficacy of PrEP in adult trials, concerns 
remain about its feasibility in real-life scenarios due to stigma, cost, and limited clinician experi-
ence with PrEP delivery. Recent studies are attempting to expand the inquiry into the efficacy 
of such HIV prophylaxis approaches in adolescent populations, but there are still many gaps in 
knowledge, and no country has yet approved it for use with adolescents. The aim of this review 
was to identify and summarize the evidence from studies on PrEP for adolescents. We have 
compiled and reviewed published studies focusing on safety, feasibility, adherence to therapeu-
tics, self-perception, and legal issues related to PrEP in people aged between 10 and 24 years.
Keywords: HIV prevention, pre-exposure prophylaxis (PrEP), adolescents, youth
Introduction
Adolescents are a critical population that is disproportionately impacted by the HIV 
epidemic. AIDS is the leading cause of death among adolescents in sub-Saharan 
Africa and is the second cause of mortality among youth worldwide.1 Over 2 million 
adolescents between the age group of 10 and 19 years are living with HIV, and millions 
more are at risk of infection every year.2
Due to fundamental neurological, psychological, and behavioral changes that take 
place during adolescence,3 this group is considered highly vulnerable to contracting 
HIV.4,5 Infection risks are considerably higher among girls, especially in high-prevalence 
settings such as eastern and southern Africa. Due to preexisting, gender-based inequali-
ties such as exclusion and sexual violence, this subgroup is disproportionately affected 
by HIV. In 2013, two-thirds of new HIV infections reported in people between the age 
group of 15 and 19 years were adolescent girls, particularly in sub-Saharan Africa.6
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Furthermore, besides young women, there are other 
youth populations that exhibit distinct sociobehavioral pat-
terns that increase their risk to contracting the virus, such 
as intravenous drug users, gay and bisexual-identifying 
teenagers, adolescent sex workers, and those who belong to 
multiple risk categories. Their public health outcomes can be 
influenced by evidence-based primary preventive strategies, 
so the focus should be on them.
Goal #3 of the United Nations’ “Sustainable Development 
Goals” (SDG3) – to ensure healthy lives and promote well-
being for all ages – requires as a target that by 2030 there 
should be an end to the epidemic of AIDS. To achieve this 
ambitious goal, each age group, population, and geographical 
location will require specific and flexible strategies.7
Pre-exposure prophylaxis (PrEP) as 
an HIV prevention strategy
PrEP is a new intervention for people at high risk to contract-
ing HIV, with an estimated HIV incidence of >3%, based on 
the use of oral antiretroviral medications to help prevent the 
infection. A daily use of two combined antiretroviral drugs 
(tenofovir disoproxil fumarate [TDF]/emtricitabine [FTC]) 
was approved as PrEP in 2012, sold under the name Truvada®
.
8
Recent data from clinical trials have demonstrated the 
efficacy of PrEP as a powerful HIV prevention tool in some 
high-risk populations including men who have sex with men,9 
HIV-1-serodiscordant heterosexual couples,10 and intrave-
nous drug users.11 PrEP effectively reduced HIV infection 
in four of six trials conducted with the adult population.9–11 
The reported efficacy in those randomized trials using TDF 
as a single agent or in combination with FTC to prevent HIV 
infection ranged from 44% to 75% and was heavily dependent 
on patient adherence (Table 1).
The Phase III randomized clinical trial PrEP initiative 
(iPrEx) highlighted the importance of adherence with over-
all protective efficacy of 44%, but as high as 92% in those 
with detectable drug levels.9 Two trials (the FEMPrEP12 and 
VOICE13) showed no significant protective effect in women, 
yet less than 30% adhered to the prescribed intervention, as 
observed through drug concentration analysis.
Despite the proven efficacy of PrEP in adult trials, there 
are concerns about real-life feasibility due to several barri-
ers including stigma, cost, and limited experience in PrEP 
delivery by HIV providers. However, some of these concerns 
abated after demonstration projects showed high clinical 
effectiveness (>80%).14,15
Recent studies are attempting to expand the investiga-
tion into the efficacy of such HIV prophylaxis approaches 
in adolescent populations. However, there are still many 
knowledge gaps, and no country has yet approved it for use 
with adolescents. Guidelines have recommended the use of 
PrEP as part of prevention for persons at substantial risk 
for HIV infection without limiting the recommendations to 
specific populations.16
The aim of this review was to identify and summarize the 
evidence from studies on PrEP for adolescents. We mapped 
published studies focusing on the safety, feasibility, accept-
ability, adherence to therapeutics, self-perception, and legal 
issues related to PrEP in people aged between 10 and 24 years.
Criteria for considering studies for 
this review
Type of studies
We considered the following study designs for inclusion:
1. Primary studies, such as randomized, quasi- randomized, 
and nonrandomized clinical trials, longitudinal obser-
vational (historical cohorts, prospective cohorts, 
case–control, and before-and-after studies), analytic 
cross-sectional studies, and non-comparative studies (case 
and series reports or single experimental cohorts).
2. Secondary studies, including systematic reviews, guide-
lines, or economic evaluations. We did not consider nar-
rative reviews, case reports, comments, or editorials.
Table 1 Clinical trials of PrEP in the population at risk of HIV infection




Partners PrEP (TDF + FTC or TDF) Heterosexual men and women 18 years or older 75 82
Botswana TDF2 (TDF + FTC) Heterosexual men and women 18 years or older 62 79
Bangkok (TDF) Drug users 18 years or older 49 67
iPrEx (TDF + FTC) Men who have sex with men 18 years or older 44 51
FemPrEP (TDF + FTC) African women 18–35 years; mean: 24.2 years 6 26
VOICE (TDF + FTC or TDF gel) Women 18–45 years; mean:25.3 years –4.2 29
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Pre-exposure prophylaxis for HIV prevention
Type of participants
Although the focus was primarily on the second decade of life, 
in some cases data on youth or young people were included. 
This inclusion is generally due to data being aggregated in 
ways that did not distinguish adolescent years specifically.
Defining overlapping terms 
“adolescents,” “youth,” and “young 
people”
The World Health Organization (WHO) defines adolescent as 
those people between 10 and 19 years of age. The United Nations 
define youth as 15–24 years, and the term “young people” is 
used by WHO and others to combine adolescents and youth.17
Outcomes of interest
We considered all effectiveness and safety outcomes for 
therapeutic studies addressing PrEP use. For all studies, we 
collected data linking PrEP use to adherence, adolescent 
self-perception, satisfaction, health care provider attitudes 
related to youth, and legal issues.
Strategy for searching studies
We conducted a systematic search of studies on 23 and 
24 January 2017 in the following databases: MEDLINE (via 
PubMed, from 1946), EMBASE (via Elsevier, from 1974), 
Cochrane Library (via Wiley, issue 1, 2017), Literatura Latino-
Americana em Ciências da Saúde e do Caribe [Latin America 
and Caribbean Health Sciences Literature] (LILACS; via Bib-
lioteca Virtual em Saúde [BVS], from 1966), and ADOLEC 
(via BVS). We also searched for ongoing or unpublished 
trials in the US National Institutes of Health Ongoing Trials 
Register (www.clinicaltrials.gov) and the WHO International 
Clinical Trials Registry Platform (ICTRP; http://apps.who.int/
trialsearch/). The search strategies are available as Appendix 1.
Study selection
Two reviewers (DMM and RR) independently assessed titles and 
abstracts from all records retrieved by the literature search for 
eligibility according to the inclusion criteria. Studies selected 
at this first stage were then evaluated in its full text to confirm 
eligibility. Disagreements between reviewers were resolved 
using consensus-based models for decision making. The selec-
tion process was performed using the Rayyan platform.18
Data extraction and presentation of 
findings
The authors extracted the data on publication, methods, and 
results of included studies. The findings are summarized in 
Tables 1 and 2 using a narrative approach.
The search strategies retrieved 521 records. The PRISMA 
diagram is shown in Figure 1.
From the 44 studies initially retrieved by the search strat-
egy, 31 were excluded, due to inclusion of participants older 
than 25 years, without depicting young people separately 
in the analysis. Of the 13 selected studies, there were six 
registered clinical trials, and two of which evaluated safety, 
feasibility, and the acceptability of daily oral TDF/FTC 
(Truvada®) specifically among adolescents.
The Adolescent Medicine Trials Network [ATN] pro-
tocol 113 (NCT01769456)19 recruited participants from 
six study sites in the USA, and the CHAMPS PillPlus 
(NCT02213328),20 in two peri-urban settings in South Africa. 
Other selected trials included participants up to 24 years of 
age combining behavioral HIV prevention interventions 
and oral PrEP. The trials and other studies in this review are 
summarized in Table 2. They also addressed several domains, 
including feasibility, medical adherence, the acceptability of 
oral daily TDF or TDF/FTC, patterns of PrEP use, patterns 
of sexual risk behavior, risk compensation, as well as cogni-
tive and emotional processes in response to using PrEP. The 
ATN 082 study compared proven behavioral HIV prevention 
interventions (Many Men, Many Voices [3MV]) alone and 
in combination with PrEP or placebo.21
There are three selected trials that are still ongoing, with 
complete results unavailable as of yet. One of which is evaluat-
ing the differences in adherence to PrEP with or without the use 
of short message service (SMS) reminders (NCT02915367).22 
The HPTN 082 trial is comparing standard adherence support 
versus enhanced counseling based on feedback from observed 
drug levels.23 Besides, qualitative research is availing the fac-
tors influencing PrEP initiation and adherence.
The NCT0281024924 has a qualitative design aims to 
identify and understand African American young men who 
have sex with men (YMSM)’s cognitive and emotional pro-
cesses in response to using PrEP to reduce their risk for HIV, 
as well as to identify what factors influence African American 
YMSM’s likely use of PrEP.
The systematic review retrieved studies’ referencing 
values and preferences among populations that might benefit 
from PrEP, as well as health care providers who may prescribe 
PrEP. Of the 76 included studies, 71 addressed adult popula-
tions. Just five studies focused on adolescent girls and young 
women.25 The substudy of Crew 450, an ongoing longitudinal 
cohort study, describes PrEP interests among racially and 
ethnically diverse YMSM aged 16–20 years, utilizing a PrEP 
interest scale with a score of the likelihood of using PrEP.26
Fisher et al27 provided empirical data on sexual and 
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Table 2 Summary of the included studies




and ATN 110 
(NCT01772823)
Country: USA (six 
study sites: Boston, 
Chicago, Los 
Angeles, Memphis, 

























Patterns of sexual 
risk behavior
Study subjects engaged in 
a behavioral risk-reduction 
intervention before PrEP.
Monthly visits for the first 
12 weeks of study.
Quarterly visits thereafter 
until 48 weeks of study
Acceptability of PrEP 
was high: -56% with TDF 
diphosphate drug levels 
consistent with ≥4 pills per 
week (at week 24) and 34% 
at week 48.
Noticeable drop-off 




Country: USA (six 
study sites: Boston, 
Chicago, Los 
Angeles, Memphis, 












youth (mean age 










alone, 3MV combined 
with PrEP (TDF/FTC), 




Acceptability of study 
design





conducted as a 2-day 
seminar throughout 
centrally located 
communities in Chicago 
with approximately eight 
participants per session.
After 3MV, study 
participants were 
randomized in blocks of 
six within each site to 
one of three study arms: 
1) daily combo FTC and 
TDF as PrEP, 2) placebo 
pill control (with HIV 
behavioral intervention), 
or (3) “no pill” control 
(subjects receive HIV 
behavioral intervention but 
no pills)
The feasibility of enrolling 
at-risk youth, particularly 
YMSM of color has been 
demonstrated.
The acceptability of the 
group intervention along 




corresponding plasma drug 
concentrations were low.
Behavioral disinhibition was 
not seen.
Decrease in sexual risk 
























daily oral TDF/FTC 
(Truvada®)
Daily oral PrEP as part of 
an HIV prevention package 
that included condoms 
and STI screening and 
treatment.
Adherence support using 
SMS, adherence clubs, 
real-time feedback on drug 
levels
Estimated date for final data 
collection date for primary 























continuation of oral 




support versus enhanced 
counseling based on 
feedback from observed 
drug levels in the first 
2 months after PrEP 
initiation.
Qualitative research about 
factors influencing PrEP 
initiation and adherence 
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1) To evaluate the 
difference in adherence 
to PrEP by the study 





Adherence Wisepill data 













1) To identify and 
understand African 
American YMSM’s 
cognitive and emotional 
processes in response 
to using PrEP to reduce 
their risk for HIV
2) To identify what 
factors (sociocultural, 
individual, experiences 
in health care, 
socioeconomic) 
influence African 
American YMSM’s likely 
use of PrEP
Individual interviews Ongoing
















To describe the 
evidence about values 
and preferences among 
populations that might 
benefit from PrEP and 
among health care 
providers who may 
prescribe PrEP
Three electronic databases 







Participants showed strong 
interest in PrEP (aged 
14–24 years).
They appreciated the 
“privacy” of a pill; some girls 
expressed hesitation with 
regard to PrEP.
Participants would be willing 
to take PrEP if it was free.
One study showed 20% of 
young women expecting to 
use condoms less frequently 
if they took PrEP
Substudy of Crew 
450 (an ongoing 
longitudinal cohort 








To describe PrEP 
interests among 
racially and ethnically 
diverse YMSM aged 
16–20 years using a 
new measure that may 
have utility in the future 
studies
Computer-assisted 
self-interview with audio 
instructions.
PrEP interest scale with a 
score of the likelihood of 
using PrEP
Participants with better 
HIV knowledge had higher 
interests in PrEP.
Higher level of education 
was related to an increased 
likelihood of taking PrEP.
No relationship between 
most of the reported risk 
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To provide empirical 
data on SGMY self-
consent that can assist 
IRBs on strategies to 
increase their research 
participation
Online survey and 
asynchronous focus group 





privacy concerns, and PrEP 
medication adherence
Adolescents have the ability 
to self-consent as compared 
to age- and population-
appropriate procedures.
Guardian permission as 
a significant barrier to 
research participation
Mack et al30










(N = 36 
participants).
Two FGs with 
adolescent aged 
14–17 years and 
two with young 
women aged 
18–24 years
To explore the 
potential role of choice 
in women’s use of HIV 
prevention methods.
To present the analysis 
of groups’ attitudes 
toward ARV-based HIV 
prevention 
All focus groups 
were audio-recorded, 
transcribed, and translated 
into English.
Transcripts were coded 
using a codebook and 
QSR NVivo 9.0 (QSR 
International, Melbourne, 
Australia); generated code 
reports; and conducted 
inductive thematic analysis 
to identify major trends 
and themes
All groups expressed strong 
interest in PrEP products.
Adolescent girls believed 
that it would be possible to 
obtain the products more 
privately than condoms.
Some girls stated that they 
would be interested in using 
PrEP only after seeing other 
girls use it.
Young women showed 
concern that it would be 
challenging to negotiate 






only online legal 
research service
A 50-state 
analysis of minor 
consent laws and 
its implications 
for PrEP
To analyze laws related 
to a minor’s ability to 
consent to medical 
care, including HIV 
diagnostic testing and 
treatment, and its 
implications for PrEP
Staff collected all statutes 
and regulations about 
an adolescent’s ability to 
consent to HIV diagnosis, 
treatment, and prevention.
On laws current as of 
December 31, 2011
Minors’ access to PrEP 
without parental consent is 
unclear.
No state expressly prohibits 
minors’ access to PrEP.
All jurisdictions allow 
adolescents to consent to 
diagnosis and treatment 
of STIs; only eight 
jurisdictions allow consent 
to prophylactic services











To examine factors 
related to the process 
by which IRBs and 
research personnel 
made decisions 
regarding whether to 
approve and implement 
the protocol.
Emphasis on the issue 
of adolescent consent 
with high-risk minor 
participants
Semi-structured interviews 
and the receipt of IRB-
related correspondence 
and documents generated 
during the review process
Of 13 ATN sites in 12 
states: seven received IRB 
approval for ATN 113, 
three were denied approval, 
and three received no 
formal IRB disposition
Abbreviations: ATN, Adolescent Medicine Trials Network; ARV, antiretroviral; FGs, focal groups; FTC, emtricitabine; IRBs, institutional review boards; PrEP, pre-exposure 
prophylaxis; SGMY, sexual and gender minority youth; SMS, short message service; STI, sexually transmitted infection; TDF, tenofovir disoproxil fumarate; 3MV, Many Men, 
Many Voices; YMSM, young men who have sex with men.
Table 2 (Continued)
institutional review boards (IRB) on strategies to increase 
their research participation. Culp and Caucci28 analyzed laws 
regarding minor’s ability to consent to medical care and its 
implications for PrEP. One substudy of ATN 113 examined 
frameworks implemented by IRBs and research personnel 
to decide whether a protocol would be accepted or not. In 
addition, an emphasis was placed on adolescent consent with 
high-risk minor participants.29
Finally, the study by Mack et al30 describes clinician 
attitudes toward, and practices around, PrEP use in youth.
Despite the encouraging results of PrEP trials in adults, 
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Pre-exposure prophylaxis for HIV prevention
is not directly transferable. Thus, data from studies including 
youth and adolescents are critical for implementation of PrEP 
in such a highly vulnerable population.
At the time of this review, there were few PrEP studies 
among adolescents with available results. One such study, 
Project PrEPare (ATN protocol 113),19 was the first adoles-
cent PrEP study among YMSM aged 15–17 years. Some 
findings of ATN 113 were initially presented at the Confer-
ence on Retroviruses and Opportunistic Infections (CROI).31
Two interconnected issues are important to highlight in 
this trial. The first is related to adherence: long-term, high 
adherence has proved to be essential for PrEP to be success-
ful. Most of the adolescents participating in project PrEPare 
achieved protective drug levels during monthly visits, but 
adherence decreased when visits became quarterly. Among 
MSM aged 18–22 years, TDF in the plasma was detectable 
in only 20% of participants at week 24.21 In the follow-up 
study, <34% had drug levels consistent with 4+ pills/week 
at week 48.31 Such a finding is in contrast to adult trends 
seen in recent trials where adherence by drug detection was 
quantified at 51–100%.32
Other important findings relate to stigma as a barrier to 
effective health interventions. Adherent participants were 
significantly less likely than non-adherents to report concerns 
about what people would think when finding they were tak-
ing PrEP pills. They anticipated the perception of stigma, 
as living with HIV meant living with the fear and effects of 
stigmatization, with consequent social rejection, discrimina-
tion, or violence.33 Likewise, previous studies have shown 
that associating PrEP with sexual risk taking may reduce 
the motivation of young people to seek PrEP or to maintain 
PrEP use for fear of stigmatization.34,35 The process of enroll-
ing adolescents in this trial was more time-consuming than 
in the parallel study group of 18–22 years (ATN protocol 
110).36 The adolescents were allowed to provide self-consent 
to participate. This approach reduced by 50% the number of 
eligible sites cleared by their IRBs to be part of the study, as 
related in the qualitative substudy of ATN 113.29
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The complexity of the legal, ethical, and practical barriers 
to conducting PrEP studies with adolescents are evident, as 
is the need for coherent and comprehensive standards for 
participation.28,29
The second trial, CHAMPS PillPlus (NCT02213328), 
included both male and female HIV-negative adolescents 
aged 16–19 years.20 Those under the age of 18 years had to 
obtain parental/guardian consent to participate in the study, 
but this requirement did not disturb the enrollment. Con-
sidering that adherence to daily medication regimens poses 
a significant challenge for adolescents, this study provided 
support using SMSs, adherence clubs, trained youth-friendly 
counselors, and real-time feedback on drug levels. A baseline 
analysis and early data from this study indicate a reasonable 
uptake and use of PrEP, based on initial plasma TDF levels. 
Those findings are encouraging, considering results from 
iPrEx indicating that PrEP reduced the risk of HIV infection 
by 92% in participants with detectable drug levels in plasma.9
Both ATN 11319 and CHAMPS20 trials showed a high 
level of acceptability to PrEP among YMSM, girls, and young 
women. Although some girls expressed hesitation with regard 
to PrEP, they appreciated the privacy of a pill and would be 
willing to take PrEP if it was provided for free in the USA. 
YMSM with better HIV knowledge and a higher level of 
education showed more interest and were more likely to 
take PrEP. Irrespective of prior knowledge, they expressed 
a desire for more information about this new prophylactic 
strategy. Prudent information for young PrEP users would 
include minimum necessary frequency of use and if gender 
would influence the overall dose to achieve similar levels of 
protection.38,39 Available data suggest that more consistent 
dosing is required to achieve sufficient levels of TDF in 
vaginal tissue when compared to rectal tissues.40 However, 
as demonstrated in the efficacy clinical trials of PrEP, women 
who were adherent to a daily PrEP regimen were strongly 
protected against HIV.10,11,41
Project PrEPare also demonstrated the feasibility of 
enrolling and retaining a young cohort of YMSM into a 
PrEP trial despite an intensive visit schedule.21 The data focus 
on YMSM and the general group of adolescents at risk for 
HIV infection. Nonetheless, the scientific health literature 
shows a lack of qualitative information on the attitudes and 
perceptions toward PrEP acceptability in other subgroups 
of adolescents such as intravenous drug users, transgender 
youth, adolescent sex workers, or teenagers in other cultural 
contexts.
Other ongoing, adolescent-inclusive trials hopefully 
will deliver more data to the discussion. One such study, 
HPTN082,23 is focused on acceptance and adherence among 
adolescents and young women aged 16–25 years.
Haberer et al42 showed that scheduled SMS reminders 
improved highly active antiretroviral therapy (HAART) in the 
context of real-time monitoring in an adult population. The 
trial NCT02915367 is assessing the use of SMS reminders (a 
behavioral intervention) to improve medication compliance in 
young people.22 A better comprehension of useful indicators 
of adherence among adolescents at high risk for HIV infec-
tion is needed to ensure the effectiveness of PrEP programs.
Young people are not at uniform risk throughout adoles-
cence, and PrEP does not need to be lifelong. As pointed by 
Hosek et al,21 “PrEP for young people may be best viewed 
as a time-limited strategy that can bridge the developmental 
period between sexual debut and adulthood.” This idea may 
have a strong impact on acceptability and points out the dif-
ference between the use of PrEP and HAART for treatment.
Combining behavioral and biomedical approaches may 
be critical to successful implementation of PrEP programs 
among youth populations. One such trial, ATN 082, shows 
the feasibility of enrolling at-risk youth with behavioral 
intervention plus biomedical prevention (PrEP) with high 
acceptability; however, the self-reported pill adherence and 
corresponding plasma drug concentrations from participants 
were low. More optimistic findings, however, were the reduc-
tion in behavioral disinhibition with decrease in risky sexual 
behavior over time.21
One of the five studies included in the systematic review 
by Koechlin et al25 was not retrieved by our search strategy, 
so it does not appear individualized in Table 2. The adoles-
cent girls showed interest in PrEP as protection from HIV, 
although a few participants appeared confused about if PrEP 
would protect them from pregnancy as well.30
One of the major concerns that could undermine PrEP 
benefits regarding risky sexual behavior is risk compensa-
tion, that is, PrEP could reduce condom use and increase 
the risk for other sexually transmitted infections (STIs).43–46 
Rubtsova et al47 found that 20% of young women expected 
to use condoms less frequently if receiving PrEP. The data 
of adolescent girls from South Africa corroborate in part 
with this concern. They found PrEP particularly appealing 
because it would eliminate concerns about being seen while 
obtaining condoms from clinics.30 The use of condoms is 
closely related to exposure to partner violence. Even the 
fear of violence is linked to women’s reluctance or inability 
to negotiate condoms or to use contraceptives.6 Indeed, if 
people were using condoms consistently, the rates of new 
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Pre-exposure prophylaxis for HIV prevention
per year.48 On the other hand, there are studies showing no 
evidence of sexual risk compensation with daily oral PrEP;49 
Mugwanya et al50 encourage the assertion that behavior 
modifications, as a result of PrEP, may not undermine the 
public health benefits of PrEP.
Regarding risk perception, persons who perceive them-
selves at high risk for HIV infection have a higher PrEP 
uptake.51 Adolescents and young people are known to have a 
lower perception of risk of being infected by HIV and other 
STIs. In Africa, young women have shown low HIV risk percep-
tion.52 The substudy of Crew 450 (YMSM aged 16–20 years) 
showed that unprotected anal intercourse had inversely propor-
tional relationship with interest in taking PrEP.26
Regarding safety, several trials in the adult population 
demonstrated a small decrease in renal function and bone 
mineral density.53–56 However, if we consider that HIV 
infection would require lifelong antiretroviral therapy, with 
increased side effect burden, PrEP use might present a favor-
able risk–benefit ratio. Safety data in PrEP studies among 
adolescents were not available as of this writing.
Although there is a promising horizon for PrEP use 
among young people, use in this population may still present 
with several challenges. One of those challenges is accept-
ability of PrEP with health care providers: knowledge and 
confidence to prescribe PrEP remains limited among clini-
cians.57–59 Mullins et al59 specifically assessed the intention 
of clinicians to prescribe PrEP to adolescents. It is clear that, 
although all the participants highlight the role of PrEP as a 
strategy to diminish the risk of acquiring HIV infection, they 
are not unanimous in prescribing it for adolescents. Fewer 
participants reported intention to prescribe PrEP for adoles-
cents, regardless of sexual orientation; many professionals 
identified a number of barriers for patients and providers, 
within the health care system and the community.
In high-incidence settings, access to PrEP could save 
money. With the ability to limit PrEP use to an identifiable 
risk period, we see increased cost savings as opposed to more 
expensive lifelong antiretroviral treatment.60
One study evaluated the laws referring to adolescent’s abil-
ity to consent to diagnostic tests, treatment and prevention of 
HIV, and other STIs.28 The possibility of minors taking PrEP 
without parental consent is unclear in the studies, which may 
complicate efforts to provide clinical care to this age group. The 
Centers for Disease Control and Prevention PrEP guidelines 
recommend that all gaps in knowledge regarding this popula-
tion are weighed against the potential benefit of providing 
PrEP for an individual adolescent at substantial risk for HIV 
infection.61 Clinicians considering providing PrEP to minors 
should observe the local laws and policies that may apply.25
Catalysts for success and barriers impacting acceptability 
and implementation of PrEP in adolescents are shown in 
Figure 2. Several topics will need to be better addressed for 
PrEP to become more widely available to youth at risk for 
HIV infection.
We faced difficulties when selecting a few studies for 
this review, because many of them did not consider particu-
larities of each age group. The available data either did not 
distinguish specific adolescent years or are a part of several 
studies that focus on the adolescence period in question, 
which are still ongoing. Such studies will provide evidence to 
Figure 2 Factors that influence acceptability and implementation of PrEP in adolescents.
Note: Arguments in favor and the issues that should be better addressed.
Abbreviation: PrEP, pre-exposure prophylaxis.
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support sound decision making by health care professionals, 
aiming to not only protect individuals but also contribute to 
the control of the HIV pandemic.
Some argue that due to cost and adherence barriers, PrEP 
will not benefit those most in need and may actually enhance 
existing HIV-associated disparities.62
The inclusion of PrEP in public programs will require 
guidance to maximize impact and effectiveness based on 
region, population group, and individual risk.63 As Aggleton64 
has remarked, “PrEP is an HIV prevention strategy that may 
be useful for some people in some contexts some of the time.” 
It is clear that the benefits of PrEP will vary across different 
programs and global regions.
Conclusion
Oral PrEP offers an exciting opportunity for adolescents and 
young adults to access a new prevention option, respecting 
their particularities and vulnerabilities. Detailed information 
about the results of available studies should be adequately 
disseminated to both the youth population and their health 
care providers to facilitate effective and safe delivery of 
PrEP. Adherence to PrEP might be facilitated by technology, 
including SMS and wireless electronic monitoring, as well 
as counseling and adherence feedback (by measuring drug 
concentration when feasible. The focus should not be to use 
PrEP indefinitely, but rather to align PrEP use with periods of 
high risk for HIV infection. It is essential to reject stereotypes 
and sex-negative messaging in guiding decisions affecting 
PrEP access and uptake, since they may contribute to enhance 
stigma. Overall, it is evident that substantial more research 
is needed focusing on adolescents and PrEP.
Each country and program should research and under-
stand the peculiar characteristics of their adolescent target 
populations – what they think, how they feel, and their 
perspectives surrounding PrEP and risky sexual behavior. 
With this information, policy makers and clinicians will be 
better equipped to serve and implement specific strategies 
that respond adequately to their health care needs.
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